Trial · NCT05528588
Furoscix in Heart Failure Patients With Diuretic Resistance
NCT05528588, Phase 2, Completed, University of Texas Southwestern Medical Center; results first posted 2025-07-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Furoscix in Heart Failure Patients With Diuretic Resistance. Trials, record NCT05528588. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05528588
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Furoscix in Heart Failure Patients With Diuretic Resistance
- NCT number
- NCT05528588
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 70 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Heart Failure
- Interventions
- Furoscix, Diuretic Therapy
- First posted
- 2022-09-06
- Last updated
- 2025-07-16
- Results first posted
- 2025-07-16
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | 1 day | Post-treatment diuretic efficiency is measured by cumulative urine output in mL per mg of treatment, observed hourly through 8 hours following the administration of study therapy (Furoscix vs. oral furosemide). |
| Secondary | Post-treatment Peak Spot Urine Sodium Levels in 1 Day | 1 day | Post-treatment peak spot urine sodium levels assessed hourly over 8 hours post-treatment. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | 1 day | mL/mg | LEAST_SQUARES_MEAN | |
| SECONDARY | Post-treatment Peak Spot Urine Sodium Levels in 1 Day | 1 day | mmol/L | LEAST_SQUARES_MEAN |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | ≥ 12 BAN-ADHF, Furoscix | 34.0 | 95% Confidence Interval 29.0 to 38.9 | mL/mg | |
| Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | <= 11 BAN-ADHF, Furoscix | 29.8 | 95% Confidence Interval 22.9 to 36.7 | mL/mg | |
| Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | ≥ 12 BAN-ADHF, Control | 22.6 | 95% Confidence Interval 17.6 to 27.6 | mL/mg | |
| Post-treatment Urine Output as Measured by Cumulative Urine Output Within 1 Day. | <= 11 BAN-ADHF, Control | 30.1 | 95% Confidence Interval 23.3 to 37.0 | mL/mg | |
| Post-treatment Peak Spot Urine Sodium Levels in 1 Day | ≥ 12 BAN-ADHF, Furoscix | 100 | 95% Confidence Interval 89 to 111 | mmol/L | |
| Post-treatment Peak Spot Urine Sodium Levels in 1 Day | <= 11 BAN-ADHF, Furoscix | 96 | 95% Confidence Interval 80 to 112 | mmol/L | |
| Post-treatment Peak Spot Urine Sodium Levels in 1 Day | ≥ 12 BAN-ADHF, Control | 83 | 95% Confidence Interval 72 to 94 | mmol/L | |
| Post-treatment Peak Spot Urine Sodium Levels in 1 Day | <= 11 BAN-ADHF, Control | 95 | 95% Confidence Interval 79 to 112 | mmol/L |
Source ClinicalTrials.gov
Participant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | ≥ 12 BAN-ADHF, Furoscix | 23 | |
| Overall Study | STARTED | <= 11 BAN-ADHF, Furoscix | 12 | |
| Overall Study | STARTED | ≥ 12 BAN-ADHF, Control | 23 | |
| Overall Study | STARTED | <= 11 BAN-ADHF, Control | 12 | |
| Overall Study | COMPLETED | ≥ 12 BAN-ADHF, Furoscix | 23 | |
| Overall Study | COMPLETED | <= 11 BAN-ADHF, Furoscix | 12 | |
| Overall Study | COMPLETED | ≥ 12 BAN-ADHF, Control | 23 | |
| Overall Study | COMPLETED | <= 11 BAN-ADHF, Control | 12 | |
| Overall Study | NOT COMPLETED | ≥ 12 BAN-ADHF, Furoscix | 0 | |
| Overall Study | NOT COMPLETED | <= 11 BAN-ADHF, Furoscix | 0 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events6
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Increase in creatinine > 0.3 from discharge to end-of-study visit blood test | Renal and urinary disorders | Subcutaneous Furosemide | 5 | 35 | |
| other | Increase in creatinine > 0.3 from discharge to end-of-study visit blood test | Renal and urinary disorders | Oral Furosemide | 3 | 35 | |
| other | Potassium ≤ 3.0 | Renal and urinary disorders | Subcutaneous Furosemide | 1 | 35 | |
| other | Potassium ≤ 3.0 | Renal and urinary disorders | Oral Furosemide | 0 | 35 | |
| serious | Emergency department visit or hospitalization for heart failure | Cardiac disorders | Subcutaneous Furosemide | 10 | 35 | |
| serious | Emergency department visit or hospitalization for heart failure | Cardiac disorders | Oral Furosemide | 13 | 35 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Subcutaneous Furosemide | 1 | 35 |
| Total, all-cause mortality | Oral Furosemide | 0 | 35 |
| Total, other adverse events | Subcutaneous Furosemide | 6 | 35 |
| Total, other adverse events | Oral Furosemide | 3 | 35 |
| Total, serious adverse events | Subcutaneous Furosemide | 10 | 35 |
| Total, serious adverse events | Oral Furosemide | 13 | 35 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Subcutaneous Furosemide vs Oral Furosemide: deaths from any cause | Trial comparisons |
| Subcutaneous Furosemide vs Oral Furosemide: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05528588
GET https://conductscience.org/api/trials/v1/NCT05528588/registered